|Bid||370.70 x 800|
|Ask||371.86 x 1000|
|Day's Range||370.42 - 379.79|
|52 Week Range||228.19 - 401.78|
|Beta (5Y Monthly)||0.62|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 31, 2023 - Feb 06, 2023|
|Forward Dividend & Yield||2.16 (0.56%)|
|Ex-Dividend Date||Aug 31, 2022|
|1y Target Est||386.85|
Despite a decline in the bottom line, Cooper Companies' (COO) fiscal fourth-quarter revenues reflect a solid segmental performance.
LabCorp's (LH) new laboratory is likely to advance clinical trials across therapeutic areas like oncology, hemato-oncology and liver diseases.
Masimo's (MASI) full-market release of the Hi for the Masimo W1 watch is likely to significantly improve RPM.